Treatment of serious infections with moxalactam (Q54501616)

30 May 2018

title

Treatment of serious infections with moxalactam (English)

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

31 August 2023

author name string

B. S. Ribner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6219576

31 August 2023

R. Raeder

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6219576

31 August 2023

T. M. Becker

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6219576

31 August 2023

E. H. Freimer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6219576

31 August 2023

language of work or name

English

0 references

publication date

1 March 1983

1 reference

30 May 2018

full work available at URL

https://api.elsevier.com/content/article/PII:0002934383909579?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

https://api.elsevier.com/content/article/PII:0002934383909579?httpAccept=text/plain

31 August 2023

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

American Journal of Medicine

31 August 2023

published in

1 reference

30 May 2018

volume

74

1 reference

30 May 2018

issue

3

1 reference

30 May 2018

page(s)

396-400

1 reference

30 May 2018

Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity

31 August 2023

2

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli

31 August 2023

3

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

Role of the 7 alpha-methoxy and side-chain carboxyl of moxalactam in beta-lactamase stability and antibacterial activity

31 August 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

Assay of antimicrobial agents

31 August 2023

5

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

Clinical evaluation of moxalactam

31 August 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

Therapy of lower respiratory tract infections with moxalactam

31 August 2023

8

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

Moxalactam therapy for a wide spectrum of bacterial infections in adults

31 August 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

Enterococcal superinfection and colonization after therapy with moxalactam, a new broad-spectrum antibiotic.

31 August 2023

10

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy

31 August 2023

11

1 reference

https://api.crossref.org/works/10.1016/0002-9343(83)90957-9

31 August 2023

Identifiers

1 reference

30 May 2018

1 reference

30 May 2018